Pierre R Leblanc, 6378 Lebanon St, Globe Village, MA 01550

2011012, Jun 2, 2011

Apr 17, 2009

12/988445

Jeffrey A. Gelfand - Cambridge MA, US
Mark C. Poznansky - Charlestown MA, US
Pierre R. Leblanc - Stoneham MA, US
Svetlana E. Korochkina - Lexington MA, US

A61K 39/395
A61K 38/02
A61K 35/00
A61K 35/76
A61K 35/74
A61K 36/06
A61K 35/68
A61K 39/00
A61K 39/12
A61K 39/02
A61P 37/04

4241781, 514 11, 424 931, 424 936, 424 937, 424 934, 424 935, 514 209, 4241931, 42419611, 42419711

Provided herein are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to four biotinylated components, and further wherein at least two of the four biotinylated components are not identical.

2022027, Sep 1, 2022

Jul 17, 2020

17/627975

- Boston MA, US
Jeffrey A. Gelfand - Cambridge MA, US
Pierre R. LeBlanc - Haverhill MA, US
Svetlana E. Korochkina - Lexington MA, US

A61K 39/00
A61P 35/00
C07K 16/28
A61K 45/06

Provided herein are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to a biotinylated component (e.g., tumor cell, tumor antigen, virus or viral antigen). The self-assembling pharmaceutical compositions may further comprise an immunotherapy (e.g., anti-PD-1 antibody). In addition, methods of using these pharmaceutical compositions to prevent and/or treat cancer, or to induce an immune response are provided. Methods of using the self-assembling pharmaceutical compositions in combination with an immunotherapy (e.g., anti-PD-1 antibody) are also provided.